we record compensation expense based on the fair value of the award at the reporting date . the awards to consultants and other third-parties are then revalued , or the total compensation is recalculated based on the then current fair value , at each subsequent reporting date . this results in a change to the amount previously recorded in respect of the equity award grant , and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used to calculate fair value , such as changes in market price , until the measurement date is reached and the compensation expense is finalized . in addition , certain restricted stock issued to employees vest upon the achievement of certain milestones ; therefore , the total expense is uncertain until the milestone is probable . our clinical trials will be lengthy and expensive . even if these trials show that our drug candidates are effective in treating certain indications , there is no guarantee that we will be able to record commercial sales of any of our drug candidates in the near future . in addition , we expect losses to continue as we continue to fund in-licensing and development of new drug candidates . as we continue our development efforts , we may enter into additional third-party collaborative agreements and may incur additional expenses , such as licensing fees and milestone payments . in addition , we may need to establish the commercial infrastructure required to manufacture , market and sell our drug candidates following approval , if any , by the fda , which would result in us incurring additional expenses . as a result , our quarterly results may fluctuate and a quarter-by-quarter comparison of our operating results may not be a meaningful indication of our future performance . 39 results of operations years ended december 31 , 2016 , 2015 and 2014 replace_table_token_6_th years ended december 31 , 2016 and 2015 license revenue . license revenue was $ 152,381 for each of the years ended december 31 , 2016 and 2015. license revenue is related to the amortization of an upfront payment of $ 2.0 million associated with our license agreement with ildong . the upfront payment from ildong will be recognized as license revenue on a straight-line basis through december 2025 , which represents the estimated period over which the company will have certain ongoing responsibilities under the sublicense agreement . noncash compensation expense ( research and development ) . noncash compensation expense ( research and development ) related to equity incentive grants totaled $ 2,742,354 for the year ended december 31 , 2016 , as compared to $ 4,261,406 during the comparable period in 2015. the decrease in noncash compensation expense was primarily related to milestone-based vesting of restricted stock grants to non-executive personnel during the year ended december 31 , 2015 , and a decrease in the measurement date fair value of certain consultant restricted stock during the year ended december 31 , 2016 . other research and development expenses . other research and development expenses increased by $ 23,044,003 from $ 43,445,817 for the year ended december 31 , 2015 to $ 66,489,820 for the year ended december 31 , 2016. the increase in other research and development expenses was due primarily to a $ 1.0 million licensing fee for the jubilant sub-license agreement , as well as the ongoing clinical development programs and related manufacturing costs for tg-1101 and tgr-1202 during the year ended december 31 , 2016. we expect our other research and development costs to increase modestly during 2017 as enrollment of additional patients in our phase 3 clinical trials increases and we prepare for a commercial launch . noncash compensation expense ( general and administrative ) . noncash compensation expense ( general and administrative ) related to equity incentive grants decreased by $ 6,668,041 from $ 11,435,686 for the year ended december 31 , 2015 to $ 4,767,645 during the year ended december 31 , 2016. the decrease in noncash compensation expense was primarily related to greater measurement date fair values of certain consultant restricted stock during the year ended december 31 , 2015 . 40 other general and administrative expenses . other general and administrative expenses increased by $ 932,202 from $ 4,189,488 for the year ended december 31 , 2015 to $ 5,121,690 for the year ended december 31 , 2016. the increase was due primarily to the straight-line rent expense of our new office space , as well as increased personnel and other general and administrative costs . we expect our other general and administrative expenses to increase modestly during 2017. other expense ( income ) , net . other income increased by $ 484,864 from $ 231,370 for the year ended december 31 , 2015 to $ 716,234 for the year ended december 31 , 2016. the increase is mainly due to the receipt of a new york city biotechnology tax credit of approximately $ 0.3 million and an increase in interest income for the year ended december 31 , 2016. years ended december 31 , 2015 and 2014 license revenue . license revenue was $ 152,381 for each of the years ended december 31 , 2015 and 2014. license revenue is related to the amortization of an upfront payment of $ 2.0 million associated with our license agreement with ildong . the upfront payment from ildong will be recognized as license revenue on a straight-line basis through december 2025 , which represents the estimated period over which the company will have certain ongoing responsibilities under the sublicense agreement . noncash stock expense associated with in-licensing agreements . story_separator_special_tag the hierarchy ranks the quality and reliability of inputs , or assumptions , used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of three categories . we elected the fair value option for valuing the 5 % notes . we elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments . recently issued accounting standards in january 2017 , the financial accounting standards board ( `` fasb `` ) issued accounting standards update ( “ asu ” ) no . 2017-04 , “ simplifying the test for goodwill impairment ” ( “ asu 2017-04 ” ) . asu 2017-04 removes the requirement to compare the implied fair value of goodwill with its carrying amount as part of step 2 of the goodwill impairment test . as a result , under asu 2017-04 , an entity should perform its annual , or interim , goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit 's fair value ; however , the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit . in addition , asu 2017-04 : ● clarifies the requirements for excluding and allocating foreign currency translation adjustments to reporting units in connection with an entity 's testing of reporting units for goodwill impairment . ● clarifies that an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss , if applicable . ● makes minor changes to the overview and background sections of certain accounting standards codification ( “ asc ” or “ codification ” ) subtopics and topics as part of the board 's initiative to unify and improve those sections throughout the codification . asu 2017-04 is effective prospectively for annual and interim periods beginning on or after december 15 , 2019 , and early adoption is permitted on testing dates after january 1 , 2017. we are currently evaluating the impact the adoption of asu 2017-04 will have on our consolidated financial statements . 45 in november 2016 , the fasb issued asu 2016-18 , “ restricted cash – a consensus of the fasb emerging issues task force ” ( “ asu 2016-18 ” ) . asu 2016-18 amends asc 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows . key requirements of the asu are as follows : ● an entity should include in its cash and cash-equivalent balances in the statement of cash flows those amounts that are deemed to be restricted cash and restricted cash equivalents . the asu does not define the terms “ restricted cash ” and “ restricted cash equivalents ” but states that an entity should continue to provide appropriate disclosures about its accounting policies pertaining to restricted cash in accordance with other gaap . the asu also states that any change in accounting policy will need to be assessed under asc 250 . ● a reconciliation between the statement of financial position and the statement of cash flows must be disclosed when the statement of financial position includes more than one line item for cash , cash equivalents , restricted cash , and restricted cash equivalents . ● changes in restricted cash and restricted cash equivalents that result from transfers between cash , cash equivalents , and restricted cash and restricted cash equivalents should not be presented as cash flow activities in the statement of cash flows . ● an entity with a material balance of amounts generally described as restricted cash and restricted cash equivalents must disclose information about the nature of the restrictions . asu 2016-18 is effective for annual and interim periods beginning after december 15 , 2017 , and early adoption is permitted for all entities . we are currently evaluating the impact the adoption of asu 2016-18 will have on our consolidated financial statements . in august 2016 , the fasb issued asu no . 2016-15 , “ classification of certain cash receipts and cash payments ” ( “ asu 2016-15 ” ) . asu 2016-15 amends the guidance in asc 230 on the classification of certain cash receipts and payments in the statement of cash flows . the primary purpose of asu 2016-15 is to reduce the diversity in practice that has resulted from the lack of consistent principles on this topic . the amendments in asu 2016-15 add or clarify guidance on eight cash flow issues : ● debt prepayment or debt extinguishment costs . ● settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing . ● contingent consideration payments made after a business combination . ● proceeds from the settlement of insurance claims . ● proceeds from the settlement of corporate-owned life insurance policies , including bank-owned life insurance policies . ● distributions received from equity method investees . ● beneficial interests in securitization transactions . ● separately identifiable cash flows and application of the predominance principle . asu 2016-15 is effective for annual and interim periods beginning after december 15 , 2017 , and early adoption is permitted for all entities . entities must apply the guidance retrospectively to all periods presented but may apply it prospectively from the earliest date practicable if retrospective application would be impracticable . the provisions of this standard are not expected to significantly impact the company . in may 2016 , the fasb issued asu no . 2016-11 , “ rescission of sec guidance because of accounting standards update 2014-09 and 2014-16 pursuant to staff announcements at the march 3 ,

liquidity and capital resources our primary sources of cash have been from the sale of equity securities , the upfront payment from our sublicense agreement with ildong , and warrant and option exercises . we have not yet commercialized any of our drug candidates and can not be sure if we will ever be able to do so . even if we commercialize one or more of our drug candidates , we may not become profitable . our ability to achieve profitability depends on a number of factors , including our ability to obtain regulatory approval for our drug candidates , successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership . we may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates . on march 9 , 2017 , we announced the pricing of an underwritten public offering of 5,128,206 shares of our common stock ( plus a 30-day option to purchase up to an additional 769,230 shares of common stock , which has been exercised ) at a price of $ 9.75 per share , with expected gross proceeds to tg therapeutics of $ 57.5 million , less underwriting discounts and commissions . total net proceeds from this offering , including the overallotment , are expected to be approximately $ 54 million , net of underwriting discounts and estimated offering expenses of approximately $ 3.5 million . the shares were sold under a shelf registration statement on form s-3 ( file no . 333-201339 ) that was previously filed and declared effective by the sec in january 2015. the offering closed on march 14 , 2017. as of december 31 , 2016 , we had $ 45.0 million in cash and cash equivalents , investment securities , and interest receivable .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```liquidity and capital resources our primary sources of cash have been from the sale of equity securities , the upfront payment from our sublicense agreement with ildong , and warrant and option exercises . we have not yet commercialized any of our drug candidates and can not be sure if we will ever be able to do so . even if we commercialize one or more of our drug candidates , we may not become profitable . our ability to achieve profitability depends on a number of factors , including our ability to obtain regulatory approval for our drug candidates , successfully complete any post-approval regulatory obligations and successfully commercialize our drug candidates alone or in partnership . we may continue to incur substantial operating losses even if we begin to generate revenues from our drug candidates . on march 9 , 2017 , we announced the pricing of an underwritten public offering of 5,128,206 shares of our common stock ( plus a 30-day option to purchase up to an additional 769,230 shares of common stock , which has been exercised ) at a price of $ 9.75 per share , with expected gross proceeds to tg therapeutics of $ 57.5 million , less underwriting discounts and commissions . total net proceeds from this offering , including the overallotment , are expected to be approximately $ 54 million , net of underwriting discounts and estimated offering expenses of approximately $ 3.5 million . the shares were sold under a shelf registration statement on form s-3 ( file no . 333-201339 ) that was previously filed and declared effective by the sec in january 2015. the offering closed on march 14 , 2017. as of december 31 , 2016 , we had $ 45.0 million in cash and cash equivalents , investment securities , and interest receivable .
```    
 Suspicious Activity Report : we record compensation expense based on the fair value of the award at the reporting date . the awards to consultants and other third-parties are then revalued , or the total compensation is recalculated based on the then current fair value , at each subsequent reporting date . this results in a change to the amount previously recorded in respect of the equity award grant , and additional expense or a reversal of expense may be recorded in subsequent periods based on changes in the assumptions used to calculate fair value , such as changes in market price , until the measurement date is reached and the compensation expense is finalized . in addition , certain restricted stock issued to employees vest upon the achievement of certain milestones ; therefore , the total expense is uncertain until the milestone is probable . our clinical trials will be lengthy and expensive . even if these trials show that our drug candidates are effective in treating certain indications , there is no guarantee that we will be able to record commercial sales of any of our drug candidates in the near future . in addition , we expect losses to continue as we continue to fund in-licensing and development of new drug candidates . as we continue our development efforts , we may enter into additional third-party collaborative agreements and may incur additional expenses , such as licensing fees and milestone payments . in addition , we may need to establish the commercial infrastructure required to manufacture , market and sell our drug candidates following approval , if any , by the fda , which would result in us incurring additional expenses . as a result , our quarterly results may fluctuate and a quarter-by-quarter comparison of our operating results may not be a meaningful indication of our future performance . 39 results of operations years ended december 31 , 2016 , 2015 and 2014 replace_table_token_6_th years ended december 31 , 2016 and 2015 license revenue . license revenue was $ 152,381 for each of the years ended december 31 , 2016 and 2015. license revenue is related to the amortization of an upfront payment of $ 2.0 million associated with our license agreement with ildong . the upfront payment from ildong will be recognized as license revenue on a straight-line basis through december 2025 , which represents the estimated period over which the company will have certain ongoing responsibilities under the sublicense agreement . noncash compensation expense ( research and development ) . noncash compensation expense ( research and development ) related to equity incentive grants totaled $ 2,742,354 for the year ended december 31 , 2016 , as compared to $ 4,261,406 during the comparable period in 2015. the decrease in noncash compensation expense was primarily related to milestone-based vesting of restricted stock grants to non-executive personnel during the year ended december 31 , 2015 , and a decrease in the measurement date fair value of certain consultant restricted stock during the year ended december 31 , 2016 . other research and development expenses . other research and development expenses increased by $ 23,044,003 from $ 43,445,817 for the year ended december 31 , 2015 to $ 66,489,820 for the year ended december 31 , 2016. the increase in other research and development expenses was due primarily to a $ 1.0 million licensing fee for the jubilant sub-license agreement , as well as the ongoing clinical development programs and related manufacturing costs for tg-1101 and tgr-1202 during the year ended december 31 , 2016. we expect our other research and development costs to increase modestly during 2017 as enrollment of additional patients in our phase 3 clinical trials increases and we prepare for a commercial launch . noncash compensation expense ( general and administrative ) . noncash compensation expense ( general and administrative ) related to equity incentive grants decreased by $ 6,668,041 from $ 11,435,686 for the year ended december 31 , 2015 to $ 4,767,645 during the year ended december 31 , 2016. the decrease in noncash compensation expense was primarily related to greater measurement date fair values of certain consultant restricted stock during the year ended december 31 , 2015 . 40 other general and administrative expenses . other general and administrative expenses increased by $ 932,202 from $ 4,189,488 for the year ended december 31 , 2015 to $ 5,121,690 for the year ended december 31 , 2016. the increase was due primarily to the straight-line rent expense of our new office space , as well as increased personnel and other general and administrative costs . we expect our other general and administrative expenses to increase modestly during 2017. other expense ( income ) , net . other income increased by $ 484,864 from $ 231,370 for the year ended december 31 , 2015 to $ 716,234 for the year ended december 31 , 2016. the increase is mainly due to the receipt of a new york city biotechnology tax credit of approximately $ 0.3 million and an increase in interest income for the year ended december 31 , 2016. years ended december 31 , 2015 and 2014 license revenue . license revenue was $ 152,381 for each of the years ended december 31 , 2015 and 2014. license revenue is related to the amortization of an upfront payment of $ 2.0 million associated with our license agreement with ildong . the upfront payment from ildong will be recognized as license revenue on a straight-line basis through december 2025 , which represents the estimated period over which the company will have certain ongoing responsibilities under the sublicense agreement . noncash stock expense associated with in-licensing agreements . story_separator_special_tag the hierarchy ranks the quality and reliability of inputs , or assumptions , used in the determination of fair value and requires financial assets and liabilities carried at fair value to be classified and disclosed in one of three categories . we elected the fair value option for valuing the 5 % notes . we elected the fair value option in order to reflect in our financial statements the assumptions that market participants use in evaluating these financial instruments . recently issued accounting standards in january 2017 , the financial accounting standards board ( `` fasb `` ) issued accounting standards update ( “ asu ” ) no . 2017-04 , “ simplifying the test for goodwill impairment ” ( “ asu 2017-04 ” ) . asu 2017-04 removes the requirement to compare the implied fair value of goodwill with its carrying amount as part of step 2 of the goodwill impairment test . as a result , under asu 2017-04 , an entity should perform its annual , or interim , goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount and should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit 's fair value ; however , the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit . in addition , asu 2017-04 : ● clarifies the requirements for excluding and allocating foreign currency translation adjustments to reporting units in connection with an entity 's testing of reporting units for goodwill impairment . ● clarifies that an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss , if applicable . ● makes minor changes to the overview and background sections of certain accounting standards codification ( “ asc ” or “ codification ” ) subtopics and topics as part of the board 's initiative to unify and improve those sections throughout the codification . asu 2017-04 is effective prospectively for annual and interim periods beginning on or after december 15 , 2019 , and early adoption is permitted on testing dates after january 1 , 2017. we are currently evaluating the impact the adoption of asu 2017-04 will have on our consolidated financial statements . 45 in november 2016 , the fasb issued asu 2016-18 , “ restricted cash – a consensus of the fasb emerging issues task force ” ( “ asu 2016-18 ” ) . asu 2016-18 amends asc 230 to add or clarify guidance on the classification and presentation of restricted cash in the statement of cash flows . key requirements of the asu are as follows : ● an entity should include in its cash and cash-equivalent balances in the statement of cash flows those amounts that are deemed to be restricted cash and restricted cash equivalents . the asu does not define the terms “ restricted cash ” and “ restricted cash equivalents ” but states that an entity should continue to provide appropriate disclosures about its accounting policies pertaining to restricted cash in accordance with other gaap . the asu also states that any change in accounting policy will need to be assessed under asc 250 . ● a reconciliation between the statement of financial position and the statement of cash flows must be disclosed when the statement of financial position includes more than one line item for cash , cash equivalents , restricted cash , and restricted cash equivalents . ● changes in restricted cash and restricted cash equivalents that result from transfers between cash , cash equivalents , and restricted cash and restricted cash equivalents should not be presented as cash flow activities in the statement of cash flows . ● an entity with a material balance of amounts generally described as restricted cash and restricted cash equivalents must disclose information about the nature of the restrictions . asu 2016-18 is effective for annual and interim periods beginning after december 15 , 2017 , and early adoption is permitted for all entities . we are currently evaluating the impact the adoption of asu 2016-18 will have on our consolidated financial statements . in august 2016 , the fasb issued asu no . 2016-15 , “ classification of certain cash receipts and cash payments ” ( “ asu 2016-15 ” ) . asu 2016-15 amends the guidance in asc 230 on the classification of certain cash receipts and payments in the statement of cash flows . the primary purpose of asu 2016-15 is to reduce the diversity in practice that has resulted from the lack of consistent principles on this topic . the amendments in asu 2016-15 add or clarify guidance on eight cash flow issues : ● debt prepayment or debt extinguishment costs . ● settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing . ● contingent consideration payments made after a business combination . ● proceeds from the settlement of insurance claims . ● proceeds from the settlement of corporate-owned life insurance policies , including bank-owned life insurance policies . ● distributions received from equity method investees . ● beneficial interests in securitization transactions . ● separately identifiable cash flows and application of the predominance principle . asu 2016-15 is effective for annual and interim periods beginning after december 15 , 2017 , and early adoption is permitted for all entities . entities must apply the guidance retrospectively to all periods presented but may apply it prospectively from the earliest date practicable if retrospective application would be impracticable . the provisions of this standard are not expected to significantly impact the company . in may 2016 , the fasb issued asu no . 2016-11 , “ rescission of sec guidance because of accounting standards update 2014-09 and 2014-16 pursuant to staff announcements at the march 3 ,

